australia
No description yet: the sentence for this tag has not been written. 11 records carry it: 11 people.
Related tags
11 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Andrew H. Wei Consultant Haematologist, Peter MacCallum Cancer Centre and Royal Melbourne Hospital; Professor, University of Melbourne · Peter MacCallum Cancer Centre Australian haematologist who led VIALE-C and QUAZAR AML-001, advancing venetoclax and oral azacitidine maintenance in AML. | Acute myeloid leukaemia | none | aml, venetoclax | ||
Anna K. Nowak Professor of Medical Oncology and Dean of Medicine, University of Western Australia · University of Western Australia Australian oncologist who led DREAM and DREAM3R, testing durvalumab with chemotherapy in mesothelioma. | Mesothelioma | none | mesothelioma, immunotherapy | ||
Anthony Lawler Head of the Therapeutic Goods Administration and Deputy Secretary, Health Products Regulation Group (since 2023) · Therapeutic Goods Administration Head of Australia's medicines and medical devices regulator, the body that approves cancer drugs for the Australian market. | none | none | leadership, regulation | ||
Constantine S. Tam Head of Lymphoma Service, Alfred Health; Professor of Haematology, Monash University · Alfred Health / Monash University Led the zanubrutinib SEQUOIA trial and the first ibrutinib-venetoclax study in mantle cell lymphoma. | Chronic lymphocytic leukaemia, Mantle cell lymphoma | none | cll, btk | ||
Georgina V. Long Co-Medical Director, Melanoma Institute Australia; Chair of Melanoma Medical Oncology and Translational Research, University of Sydney · Melanoma Institute Australia Melanoma trialist who led COMBI-d, COMBI-AD and NADINA, moving immunotherapy before surgery for stage III disease. | Melanoma | none | melanoma, neoadjuvant | ||
John F. Seymour Director of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital · Peter MacCallum Cancer Centre Led MURANO, which established venetoclax plus rituximab as fixed-duration therapy for relapsed CLL. | Chronic lymphocytic leukaemia | none | cll, venetoclax | ||
Linda Mileshkin Medical Oncologist and Director of Clinical Trials, Peter MacCallum Cancer Centre · Peter MacCallum Cancer Centre Led OUTBACK, which showed adding chemotherapy after chemoradiation does not help cervical cancer, a key negative result. | Cervical cancer, Cancer of unknown primary | none | cervical, cooperative-group | ||
Louise Emmett Director of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney; Professor, UNSW · Garvan Institute of Medical Research / Kinghorn Cancer Centre Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics. | Prostate cancer | none | prostate, radioligand | ||
Michael Dickinson Lead, Aggressive Lymphoma Program, Peter MacCallum Cancer Centre and Royal Melbourne Hospital · Peter MacCallum Cancer Centre Led the pivotal glofitamab trial, establishing off-the-shelf bispecific antibodies for relapsed large B-cell lymphoma. | Diffuse large B-cell lymphoma | none | lymphoma, bispecific | ||
Shankar Siva Professor and Director of Radiation Oncology Research, Peter MacCallum Cancer Centre · Peter MacCallum Cancer Centre Radiation oncologist who established stereotactic radiotherapy as a non-surgical option for primary kidney cancer. | Renal cell carcinoma, Prostate cancer | none | radiotherapy, sbrt, kidney | ||
Timothy P. Hughes Consultant Haematologist, Royal Adelaide Hospital; Cancer Theme Leader, South Australian Health and Medical Research Institute · Royal Adelaide Hospital Defined molecular response monitoring in CML and showed that many patients can safely stop imatinib. | Chronic myeloid leukaemia | none | cml, molecular-monitoring |
